Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
Chubb
Citi
Federal Trade Commission
Fuji
Argus Health
Fish and Richardson
Johnson and Johnson
Novartis

Generated: October 23, 2017

DrugPatentWatch Database Preview

OMNIPAQUE 350 Drug Profile

« Back to Dashboard

Which patents cover Omnipaque 350, and when can generic versions of Omnipaque 350 launch?

Omnipaque 350 is a drug marketed by Ge Healthcare and is included in two NDAs.

The generic ingredient in OMNIPAQUE 350 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.

Summary for Tradename: OMNIPAQUE 350

US Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list2
Bulk Api Vendors: see list46
Clinical Trials: see list332
Patent Applications: see list1,193
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OMNIPAQUE 350 at DailyMed

Pharmacology for Tradename: OMNIPAQUE 350

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
OMNIPAQUE 350
iohexol
SOLUTION;INJECTION, ORAL020608-003Oct 24, 1995RXNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
OMNIPAQUE 350
iohexol
SOLUTION;INJECTION, ORAL018956-004Dec 26, 1985RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OMNIPAQUE 350

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare
OMNIPAQUE 350
iohexol
SOLUTION;INJECTION, ORAL018956-004Dec 26, 1985► Subscribe► Subscribe
Ge Healthcare
OMNIPAQUE 350
iohexol
SOLUTION;INJECTION, ORAL018956-004Dec 26, 1985► Subscribe► Subscribe
Ge Healthcare
OMNIPAQUE 350
iohexol
SOLUTION;INJECTION, ORAL018956-004Dec 26, 1985► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Accenture
Express Scripts
Harvard Business School
Dow
Healthtrust
Johnson and Johnson
Federal Trade Commission
Novartis
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot